Tiseo M; Boni C; Baldini E; Boni L; Recchia F; Barone C; Manzione L; Grossi F; Matano E; Zanelli F; Prochilo T; Ardizzoni A, Triplets versus doublets with or without cisplatin in the first-line treatment of stage IIIB-IV nonsmall cell lung cancer (NSCLC) patients: Preliminary results of a multicenter randomized factorial study, «ANNALS OF ONCOLOGY», 2007, 18, pp. 36 - 36 [abstract]
Boni L; Sormani MP; Bruzzi P; Tiseo M; Rosell R; Ardizzoni A, Tumor response to chemotherapy as a surrogate endpoint of survival in advanced non-small cell lung cancer (NSCLC): Results of an individual patients data meta-analysis, «ANNALS OF ONCOLOGY», 2007, 18, pp. 24 - 24 [abstract]
Tiseo M; Franciosi V; Grossi F; Ardizzoni A, Adjuvant chemotherapy for non-small cell lung cancer: Ready for clinical practice?, «EUROPEAN JOURNAL OF CANCER», 2006, 42, pp. 8 - 16 [replica/breve intervento]
Ardizzoni A; Tiseo M; Boni L; Rosell R; Fossella FV; Schiller JH; Paesmans M; Radosavljevic D; Paccagnella A; Mazzanti P; Bisset D, CISCA (cisplatin vs. carboplatin) meta-analysis: An individual patient data meta-analysis comparing cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC)., «JOURNAL OF CLINICAL ONCOLOGY», 2006, 24, pp. 366S - 366S [abstract]
Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M, Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer, «CANCER», 2006, 107, pp. 2842 - 2849 [replica/breve intervento]
Bozzetti C; Musolino A; Camisa R; Bisagni G; Flora M; Bassano C; Martella E; Lagrasta C; Nizzoli R; Personeni N; Leonardi F; Cocconi G; Ardizzoni A, Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer - The role of anthrocycline dose intensity, «AMERICAN JOURNAL OF CLINICAL ONCOLOGY: CANCER CLINICAL TRIALS», 2006, 29, pp. 171 - 177 [replica/breve intervento]
Scartozzi M; Franciosi V; Campanini N; Benedetti G; Barbieri F; Rossi G; Berardi R; Camisa R; Silva RR; Santineelli A; Ardizzoni A; Crino L; Rindi G; Cascinu S, Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients, «LUNG CANCER», 2006, 53, pp. 103 - 109 [replica/breve intervento]
Tiseo M; Franciosi V; Ardizzoni A, Multi-target inhibitors in non-small cell lung cancer (NSCLC), «ANNALS OF ONCOLOGY», 2006, 17, pp. 55 - 57 [replica/breve intervento]
Ardizzoni A; Tiseo M, Novel targeted approaches in non-small cell lung cancer (NSCLC), «ANNALS OF ONCOLOGY», 2006, 17, pp. V91 - V93 [replica/breve intervento]
Musolino A; Naldi N; Michiara M; Bella MA; Zanelli P; Bortesi B; Capelletti M; Savi M; Neri TM; Ardizzoni A, A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes, «BREAST CANCER RESEARCH AND TREATMENT», 2005, 91, pp. 203 - 205 [replica/breve intervento]
Scagliotti GV; Smit E; Bosquee L; O'Brien M; Ardizzoni A; Zatloukal P; Eberhardt W; Smid-Geirnaerdt M; de Bruin HG; Dussenne S; Legrand C; Giaccone G, A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956), «LUNG CANCER», 2005, 50, pp. 91 - 96 [replica/breve intervento]
Tiseo M; Monetti E; Ferrarini M; Serrano J; Chiaramondia M; Ardizzoni A, Dramatic responses to therapy in rare tumors, «JOURNAL OF CLINICAL ONCOLOGY», 2005, 23, pp. 1578 - 1579 [replica/breve intervento]
Loprevite M; Tiseo M; Grossi F; Scolaro T; Semino C; Pandolfi A; Favoni R; Ardizzoni A, In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines, «ONCOLOGY RESEARCH», 2005, 15, pp. 39 - 48 [replica/breve intervento]
Ardizzoni A; Scolaro T; Mereu C; Cafferata MA; Tixi L; Bacigalupo A; Tiseo M; Monetti F; Rosso R, Induction chemotherapy with carboplatin-paclitaxel followed by standard radiotherapy with concurrent daily low-dose cisplatin plus weekly paclitaxel for inoperable non-small-cell lung cancer, «AMERICAN JOURNAL OF CLINICAL ONCOLOGY: CANCER CLINICAL TRIALS», 2005, 28, pp. 58 - 64 [replica/breve intervento]
Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G, Lomustine (Chloroethyinitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma, «CANCER», 2005, 103, pp. 2109 - 2117 [replica/breve intervento]
